Lawsuits, Just the Cost of Criminal Marketing of Antipsychotic Drugs

"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.” Continue reading →

AHRP Letter to Harvard Re: Dr. Biederman’s Research

ahrp_logo.jpg

AHRP proposes a multi-disciplinary team of independent scientists to review ALL of Dr. Joseph Biederman’s publications and supporting documents, including: research protocols, consent forms, and the original (of course, anonymized) data sets with associated code books for all pediatric studies. Continue reading →

Florida Antipsychotic Pre-Approval Requirement Protects PreschoolChildren

The State of Florida has established a pre-approval requirement to protect preschool children on Medicaid from being exposed to the hazardous effects of antipsychotic drugs. That step has prompted "a seismic change" in doctors’ inappropriate prescribing of antipsychotics for preschool children: the . . . Continue reading →

Sen. Grassley Letter to Harvard: Biederman Research Protocol Breaches

The most shocking disclosure is that Dr. Biederman’s study testing powerful antipsychotics in PRESCHOOL CHILDREN "was beset by breaches of research protocol," Continue reading →

Letter of Complaint to FDA Commissioner, 2007

vera_signature.png

Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without  an advisory panel or open public discussion.  Continue reading →

Babies given mind altering drugs in Florida / 68 Paxil Withdrawal Victims File Lawsuit

Babies given mind altering drugs in Florida / 68 Paxil Withdrawal Victims File Lawsuit Wed, 24 Sep 2003 The serious problems that children in foster care have, are compounded by the scourge of psychotropic drugs which they are forced to take. The . . . Continue reading →

AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising

AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re:  Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant . . . Continue reading →

SAMHSA Backs Away From TeenScreen & TMAP

SAMHSA Backs Away From TeenScreen & TMAP Mon, 24 Oct 2005 On October 17, a meeting took place with Charles Currie in Washington DC – with some in attendance by conference call. Currie is the Administrator of the Substance Abuse and Mental . . . Continue reading →

What’s New? – Alliance for Human Research Protection

To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical . . . Continue reading →

Featured News

AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New . . . Continue reading →